BAY1747846
Sponsors
Bayer
Conditions
Contrast Enhancement in Magnetic Resonance ImagingHealthy Volunteers
Phase 1
A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function
CompletedNCT05061979
Start: 2021-10-12End: 2022-07-14Updated: 2022-11-21
A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants
CompletedNCT06125366
Start: 2019-04-17End: 2019-07-11Updated: 2023-11-09